These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20339887)

  • 1. A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.
    Sanna D; Buglyó P; Micera G; Garribba E
    J Biol Inorg Chem; 2010 Aug; 15(6):825-39. PubMed ID: 20339887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.
    Sanna D; Micera G; Garribba E
    Inorg Chem; 2010 Jan; 49(1):174-87. PubMed ID: 19947643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of VO2+ ion and some insulin-enhancing compounds with immunoglobulin G.
    Sanna D; Micera G; Garribba E
    Inorg Chem; 2011 Apr; 50(8):3717-28. PubMed ID: 21434616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speciation of potential anti-diabetic vanadium complexes in real serum samples.
    Sanna D; Ugone V; Serra M; Garribba E
    J Inorg Biochem; 2017 Aug; 173():52-65. PubMed ID: 28499214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of insulin-enhancing vanadium compounds with human serum holo-transferrin.
    Sanna D; Micera G; Garribba E
    Inorg Chem; 2013 Oct; 52(20):11975-85. PubMed ID: 24090437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
    Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
    J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 2. Characterization of sulfonate derivatives of quercetin and morin, interaction with the bioligands of the plasma and preliminary biotransformation studies.
    Sanna D; Ugone V; Pisano L; Serra M; Micera G; Garribba E
    J Inorg Biochem; 2015 Dec; 153():167-177. PubMed ID: 26281973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the binding of oxovanadium(IV) to human serum albumin.
    Correia I; Jakusch T; Cobbinna E; Mehtab S; Tomaz I; Nagy NV; Rockenbauer A; Pessoa JC; Kiss T
    Dalton Trans; 2012 Jun; 41(21):6477-87. PubMed ID: 22476413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the transport of vanadium in blood serum.
    Sanna D; Micera G; Garribba E
    Inorg Chem; 2009 Jul; 48(13):5747-57. PubMed ID: 19514735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport of the anti-diabetic VO2+ complexes formed by pyrone derivatives in the blood serum.
    Sanna D; Bíró L; Buglyó P; Micera G; Garribba E
    J Inorg Biochem; 2012 Oct; 115():87-99. PubMed ID: 22926028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of antidiabetic vanadium compounds with hemoglobin and red blood cells and their distribution between plasma and erythrocytes.
    Sanna D; Serra M; Micera G; Garribba E
    Inorg Chem; 2014 Feb; 53(3):1449-64. PubMed ID: 24437949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of VO2+ ion with human serum transferrin and albumin.
    Sanna D; Garribba E; Micera G
    J Inorg Biochem; 2009 Apr; 103(4):648-55. PubMed ID: 19201482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical speciation of insulinomimetic VO(IV) complexes of pyridine-N-oxide derivatives: binary and ternary systems.
    Kiss E; Kawabe K; Tamura A; Jakusch T; Sakurai H; Kiss T
    J Inorg Biochem; 2003 Jun; 95(2-3):69-76. PubMed ID: 12763650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temperature and solvent structure dependence of VO2+ complexes of pyridine-N-oxide derivatives and their interaction with human serum transferrin.
    Sanna D; Ugone V; Micera G; Garribba E
    Dalton Trans; 2012 Jun; 41(24):7304-18. PubMed ID: 22576640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and biotransformation in the plasma and red blood cells of V(IV)O(2+) complexes formed by ceftriaxone.
    Sanna D; Fabbri D; Serra M; Buglyó P; Bíró L; Ugone V; Micera G; Garribba E
    J Inorg Biochem; 2015 Jun; 147():71-84. PubMed ID: 25601642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
    Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
    J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum.
    Kiss T; Kiss E; Garribba E; Sakurai H
    J Inorg Biochem; 2000 May; 80(1-2):65-73. PubMed ID: 10885465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications.
    Del Carpio E; Hernández L; Ciangherotti C; Villalobos Coa V; Jiménez L; Lubes V; Lubes G
    Coord Chem Rev; 2018 Oct; 372():117-140. PubMed ID: 32226092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ternary complex formation between VO(IV)-picolinic acid or VO(IV)-6-methylpicolinic acid and small blood serum bioligands.
    Kiss E; Garribba E; Micera G; Kiss T; Sakurai H
    J Inorg Biochem; 2000 Jan; 78(2):97-108. PubMed ID: 10766332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biospeciation of various antidiabetic V(IV)O compounds in serum.
    Jakusch T; Hollender D; Enyedy EA; González CS; Montes-Bayón M; Sanz-Medel A; Costa Pessoa J; Tomaz I; Kiss T
    Dalton Trans; 2009 Apr; (13):2428-37. PubMed ID: 19290378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.